Development of an optimized dual-targeted tandem VH-only fully-human CAR to generate long-term durable remission with adoptive cellular therapy for multiple myeloma

Basic Information

Funding Cycle : 2022-2023, 2023-2024
Name : Eric Smith
Type of Award : Translational Research Award
Home Institution : Dana-Farber Cancer Institute


This project aims to develop an optimized dual-targeted tandem VH-only fully-human CAR for the treatment of multiple myeloma, aiming to achieve durable remissions. Specific aims include analyzing factors associated with CAR T cell manufacturing success, predicting CAR T cell expansion post-infusion, correlating T cell composition with side effects, identifying markers for treatment response and resistance, and comparing T cell compartments from leukapheresis and autologous stem cell products. The project leverages previous advancements in CAR T cell therapy to enhance efficacy while minimizing toxicity, ultimately aiming to advance the therapy towards clinical translation.

Why Become a Member

The International Myeloma Society is a professional, scientific, and medical society established to bring together clinical and experimental scientists involved in the study of myeloma. The purpose of this society is to promote research, education, clinical studies (including diagnosis and treatment), workshops, conferences, and symposia on all aspects of multiple myeloma worldwide.

The IMS is a membership organization comprised of basic research scientists, and clinical investigators in the field along with physicians and other healthcare practitioners.

Stay updated on our Events